<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142125</url>
  </required_header>
  <id_info>
    <org_study_id>CATIS-ICAD</org_study_id>
    <nct_id>NCT04142125</nct_id>
  </id_info>
  <brief_title>Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease</brief_title>
  <official_title>Combination Anti-thrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease: Protocol for a Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke,&#xD;
      that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due&#xD;
      to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban +&#xD;
      aspirin or aspirin alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>investigator-initiated, open-label, blinded endpoint assessment, controlled, randomized pilot trial (PROBE design)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded assessment of endpoint</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>From randomization to end of recruitment (2 years)</time_frame>
    <description>Recruitment rate of potentially eligible patients from neurology clinics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Refusal rate</measure>
    <time_frame>From randomization to end of recruitment (2 years)</time_frame>
    <description>Rate of patients who refuse to participate in the clinical trial who otherwise are eligible for the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention rate</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Rate of patients who remain in the clinical trial until EOS or qualifying event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of Intracranial hemorrhage</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Rate of patients who experience an intracranial hemorrhage during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Major hemorrhage as defined by ISTH criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of ISTH major hemorrhages &amp; clinically-relevant non-major hemorrhages</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Major hemorrhage and clinically relevant non-major as per ISTH criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent ischemic stroke &amp; MRI-detected incident covert brain infarction</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Symptomatic investigator reported ischemic stroke and MRI detected covert brain infarct as determined by MRI corelab reading baseline and end of study MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent ischemic stroke</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Recurrent ischemic stroke that is restricted to the area of the qualifying stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of stroke, myocardial infarction or vascular death</measure>
    <time_frame>From randomization to End of Study (median 2 years)</time_frame>
    <description>Composite of stroke, MI or vascular death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracranial Atherosclerotic Disease</condition>
  <arm_group>
    <arm_group_label>Experimental (riva + ASA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 2.5mg bid + aspirin 81mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (ASA alone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 Mg Oral Tablet bid</intervention_name>
    <description>Pts will receive rivaroxaban + aspirin</description>
    <arm_group_label>Experimental (riva + ASA)</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicyclic acid 81 mg tablet qd</intervention_name>
    <description>Pts will receive ASA</description>
    <arm_group_label>Control (ASA alone)</arm_group_label>
    <arm_group_label>Experimental (riva + ASA)</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 40 years&#xD;
&#xD;
          2. Recent brain ischemia attributed to intracranial atherosclerotic stenosis of 30-99% as&#xD;
             evidenced by CT or MR angiography, occurring between 7 to 100 days prior to&#xD;
             randomization and consisting of either:&#xD;
&#xD;
               1. a high-risk TIA defined as TIA with motor and/or speech involvement or&#xD;
&#xD;
               2. an ischemic stroke&#xD;
&#xD;
          3. Written informed consent consistent with local regulations governing research in human&#xD;
             subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indication for DAPT for &gt; 90 days on guideline recommendations or investigator ́s&#xD;
             judgment; e.g., cardiac stenting.&#xD;
&#xD;
          2. Indication for chronic anticoagulation based on guideline recommendations or&#xD;
             investigator ́s judgment; e.g. patient with prosthetic mechanical valve, venous&#xD;
             thromboembolism, hypercoagulable state&#xD;
&#xD;
          3. Atrial fibrillation or a history of atrial fibrillation&#xD;
&#xD;
          4. Intracranial arterial occlusion (e.g. 100% stenosis) responsible for the acute brain&#xD;
             ischemia&#xD;
&#xD;
          5. Intracranial arterial stenosis secondary to causes other than atherosclerosis&#xD;
&#xD;
          6. Extracranial carotid artery disease ipsilateral to the qualifying brain ischemia with&#xD;
             a plan for carotid revascularization&#xD;
&#xD;
          7. Intraluminal thrombus&#xD;
&#xD;
          8. Subdural hematoma within 12 months of randomization&#xD;
&#xD;
          9. Previous spontaneous hemorrhagic stroke (e.g. intracerebral or subarachnoid&#xD;
             hemorrhage)&#xD;
&#xD;
         10. Traumatic brain hemorrhage within 1 month of randomization&#xD;
&#xD;
         11. Contraindication for MRI scan (e.g. pacemaker incompatible with MRI)&#xD;
&#xD;
         12. Advanced kidney disease (recent estimated GFR &lt;30 ml per minute)&#xD;
&#xD;
         13. Modified Rankin Scale (mRS) &gt;=4 at entry&#xD;
&#xD;
         14. Platelet count less than 100,000/mm3 at enrolment or other bleeding diathesis&#xD;
&#xD;
         15. Uncontrollable hypertension with systolic BP/ diastolic BP consistently&#xD;
             above180/100mmHg after treatment&#xD;
&#xD;
         16. Known hypersensitivity to either ASA or rivaroxaban&#xD;
&#xD;
         17. Life expectancy less than 6 months&#xD;
&#xD;
         18. Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4)&#xD;
             and P-glycoprotein (P-gp), i.e., human immunodeficiency virus protease inhibitors and&#xD;
             the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, or&#xD;
             posaconazole, if used systemically&#xD;
&#xD;
         19. Female of childbearing potential who are not surgically sterile, or, if sexually&#xD;
             active not willing to use adequate contraceptive measures with a failure rate less&#xD;
             than 1% per year (e.g., prescription oral contraceptives, contraceptive injections,&#xD;
             intrauterine device, double-barrier method, male partner sterilization) before entry&#xD;
             and throughout the study, as well as pregnant or breast-feeding women&#xD;
&#xD;
         20. Inability to adhere to study procedures&#xD;
&#xD;
         21. Close affiliation with the investigational site; e.g. a close relative of the&#xD;
             investigator, dependent person (e.g., employee or student of the investigational site)&#xD;
&#xD;
         22. Previous randomization to this study or participating in a study with an&#xD;
             investigational drug or medical device at the time of randomization&#xD;
&#xD;
         23. Antiphospholipid antibody syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanjana S. Perera, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Taylor</last_name>
    <phone>905.527.4322</phone>
    <phone_ext>40508</phone_ext>
    <email>CATIS-ICAD@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Cheng</last_name>
    <phone>905.527.4322</phone>
    <phone_ext>41089</phone_ext>
    <email>CATIS-ICAD@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhema Research Institute</name>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <zip>N4K 6M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pilot study</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Factor Xa Inhibitors</keyword>
  <keyword>Intracranial Atherosclerotic Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

